Microglia are the resident immune cells of the central nervous system (CNS) and serve as the primary mediators of neuroinflammation in neurodegenerative diseases[1]. In their resting state, microglia perform essential homeostatic functions including synaptic pruning, debris clearance, and trophic support. However, in response to pathological stimuli associated with Alzheimer's disease, Parkinson's disease, and related disorders, microglia undergo a transition to chronic activation states that can drive progressive neurodegeneration through sustained production of pro-inflammatory cytokines, reactive oxygen species, and neurotoxic factors[2].
The dual nature of microglia—capable of both neuroprotection and neurotoxicity—makes them central therapeutic targets in neurodegenerative disease. Understanding the mechanisms that govern the transition from beneficial acute responses to detrimental chronic inflammation is essential for developing disease-modifying therapies.
| Property | Value |
|---|---|
| Cell Type | Resident CNS macrophage, yolk sac origin |
| Population | ~10-15% of CNS cells (~100 billion in human brain) |
| Distribution | Throughout CNS, regional heterogeneity |
| Activation Spectrum | Resting → Reactive → Chronic disease-associated |
| Key Functions | Surveillance, phagocytosis, cytokine production, antigen presentation |
| Disease Markers | CD68+, CD11b+, Iba1+, TSPO+, HLA-DR+ |
| Neurotoxic Mediators | IL-1β, TNF-α, IL-6, NO, ROS, glutamate |
| Neuroprotective Factors | BDNF, IGF-1, TGF-β, IL-10 |
Up --> EarlyDAM
EarlyDAM --> TREM2Sign --> FullDAM
FullDAM --> Phago
FullDAM --> Lipid
Phago --> Protective
Lipid --> Maladaptive
FullDAM --> Maladaptive
### Senescent Microglia
Aged and chronically activated microglia develop a senescent phenotype [^4]:
- **SASP factors**: IL-1β, IL-6, TNF-α, MMP-9
- **Reduced phagocytosis**: Impaired debris clearance
- **DNA damage response**: Persistent γH2AX foci
- **Lysosomal dysfunction**: Lipofuscin accumulation
- **Metabolic shifts**: Reduced oxidative phosphorylation
## Mechanisms of Neurotoxicity
### Cytokine-Mediated Effects
| Cytokine | Receptor | Neurotoxic Effect | Disease Evidence |
|----------|----------|-------------------|------------------|
| **TNF-α** | TNFR1/2 | Apoptosis, synaptic dysfunction | Elevated in AD, PD CSF |
| **IL-1β** | IL-1R1 | Impairs LTP, promotes tau | Increased in AD brain |
| **IL-6** | IL-6R/gp130 | Disrupts plasticity, astrogliosis | Correlates with cognitive decline |
| **IL-18** | IL-18R | Synergizes with IL-1β | Elevated in AD |
| **CCL2 (MCP-1)** | CCR2 | Monocyte recruitment | Predicts cognitive decline |
### NLRP3 Inflammasome Activation
The NLRP3 inflammasome is a critical driver of chronic neuroinflammation [^5]:
```mermaid
flowchart LR
subgraph PrimingSig["Signal 1: Priming"]
TLR4["TLR4/NF-kB"]
IL1R["IL-1R/NF-kB"]
Transcription["Transcription of<br/>NLRP3, pro-IL-1b, pro-IL-18"]
end
subgraph ActivationSig["Signal 2: Activation"]
AbOligo["Ab Oligomers"]
TauAgg["Tau Aggregates"]
aSyn["a-Synuclein"]
ATP["Extracellular ATP"]
ROS["ROS/Mitochondrial<br/>Dysfunction"]
end
subgraph InflammasomeAsm["NLRP3 Inflammasome Assembly"]
NLRP3sensor["NLRP3 Sensor"]
ASCadaptor["ASC Adaptor<br/>(PYCARD)"]
Caspase1["Caspase-1"]
end
subgraph ProductsSig["Inflammatory Products"]
IL1b["Active IL-1b<br/>(Neurotoxic)"]
IL18["Active IL-18<br/>(Neurotoxic)"]
Pyroptosis["Pyroptotic Cell<br/>Death (GSDMD)"]
end
PrimingSig --> Transcription
ActivationSig --> InflammasomeAsm
NLRP3sensor --> ASCadaptor --> Caspase1
Caspase1 --> ProductsSig
Activated microglia release glutamate through:
Microglial dysfunction in AD involves multiple pathways[3]:
AD Microglia Phenotype Progression:
| Target | Agent | Status | Notes |
|---|---|---|---|
| TSPO | PET ligands, potential therapeutics | Imaging standard | Activated microglia marker |
| NLRP3 | MCC950, dapansutrile | Preclinical/Early trials | Inflammasome blockade |
| TNF-α | Etanercept, infliximab | Mixed results | CNS penetration challenge |
| IL-1β | Canakinumab, anakinra | Limited efficacy | May need early intervention |
| CSF1R | PLX3397, PLX5622 | Preclinical | Microglial depletion |
TSPO-PET: First-generation (PK11195), second-generation (PBR28, DPA-713)
MR Spectroscopy: Myo-inositol as gliosis marker
Dynamic contrast MRI: Blood-brain barrier integrity
[Microglia](/cell-types/microg- NLRP3 Inflammasome
NLRP3 Inflammasome TREM2
Senolytics for Neurodegeneration
Complement System in Neurodegeneration
Heneka MT, et al. Neuroinflammation in Alzheimer's disease. Lancet Neurology. 2015. ↩︎
Block ML, et al. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nature Reviews Neuroscience. 2007. ↩︎
Ransohoff RM. How neuroinflammation contributes to neurodegeneration. Science. 2016. ↩︎